# Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

> **NCT05297240** · — · UNKNOWN · sponsor: **PETHEMA Foundation** · enrollment: 170 (estimated)

## Conditions studied

- RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

## Interventions

- **DRUG:** Belantamab mafodotin

## Key facts

- **NCT ID:** NCT05297240
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-24
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2022-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297240, "Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05297240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*